For U.S. Healthcare Professionals Only

Instructions for Use:

75 mg Pen 150 mg Pen

Appropriate Patients

In adults with established CV disease,

Choose PRALUENT

Expand All | Collapse All

GETTING GEORGE TO LDL-C GOAL

BASELINE

George had a baseline LDL-C of 190 mg/dL and was started on rosuvastatin 20 mg/day

AT 12 MONTHS

He had an MI and his treatment was intensified to rosuvastatin 40 mg/day

AT 14 MONTHS

He still was not at his target LDL-C (<70 mg/dL), and PRALUENT was added to his treatment regimen

TODAY

George has reached his LDL-C goal

Help patients like George. Learn how PRALUENT reduced CV events (MI, stroke, UA requiring hospitalization).3

See data from ODYSSEY OUTCOMES here

1 in 3 adults who survive an MI or stroke will experience another CV event within 4 years4

Based on a 4-year follow-up of over 20,000 people who had a prior MI or stroke; CV event is defined as CV death, MI, stroke, or rehospitalization

GETTING SHARON TO LDL-C GOAL

BASELINE

Sharon had a baseline LDL-C of 160 mg/dL and was started on atorvastatin 40 mg/day

AT 12 MONTHS

She was hospitalized for unstable angina and her treatment was switched to rosuvastatin 40 mg/day

AT 14 MONTHS

She still was not at her target LDL-C (<70 mg/dL), and PRALUENT was added to her treatment regimen

TODAY

Sharon has reached her LDL-C goal

Help patients like Sharon. Learn how PRALUENT reduced CV events (MI, stroke, UA requiring hospitalization).3

See data from ODYSSEY OUTCOMES here

1 in 3 adults who survive an MI or stroke will experience another CV event within 4 years4

Based on a 4-year follow-up of over 20,000 people who had a prior MI or stroke; CV event is defined as CV death, MI, stroke, or rehospitalization

GETTING MICHELLE TO LDL-C GOAL

BASELINE

Michelle had a baseline LDL-C of 260 mg/dL and was started on pravastatin 80 mg/day

AT 12 MONTHS

She had a CV event and her treatment was switched to rosuvastatin 40 mg/day

AT 14 MONTHS

She still was not at her target LDL-C (<100 mg/dL), and PRALUENT was added to her treatment regimen

TODAY

Michelle has reached her LDL-C goal

Help patients like Michelle. Learn how PRALUENT reduced LDL-C.3

See data from the FH I and FH II studies here

*Target LDL-C according to ACC/AHA 2018 guidelines: <70 mg/dL in patients with clinical ASCVD who are judged to be very high risk, or <100 mg/dL for patients who are 30 to 75 years of age with heterozygous FH and on maximally tolerated LDL-C lowering therapy.1

NEED HELP? CONTACT A REP

Learn more about the appropriate patient for PRALUENT from a PRALUENT Field Representative

CLINICAL OVERVIEW

Learn about CV outcomes results for PRALUENT

Learn about CV outcomes results for PRALUENT

PRALUENT ACCESS & AFFORDABILITY

Help your patients with accessibility, affordability & dosing flexibility

Help your patients with accessibility, affordability & dosing flexibility

Find potential patients for PRALUENT with your EHR system
Select a category below to download a tip sheet and learn how to use your office’s existing EHR system to:
INDICATIONS AND USAGE

PRALUENT (alirocumab) is indicated:

  • to reduce the risk of myocardial infarction, stroke, and unstable angina requiring hospitalization in adults with established cardiovascular disease.
  • as an adjunct to diet, alone or in combination with other lipid-lowering therapies (e.g., statins, ezetimibe), for the treatment of adults with primary hyperlipidemia (including heterozygous familial hypercholesterolemia) to reduce low-density lipoprotein cholesterol (LDL-C).
IMPORTANT SAFETY INFORMATION
  • PRALUENT is contraindicated in patients with a history of a serious hypersensitivity reaction to PRALUENT, including hypersensitivity vasculitis and hypersensitivity reactions requiring hospitalization
  • Hypersensitivity reactions (e.g., pruritus, rash, urticaria), including some serious events (e.g., hypersensitivity vasculitis and hypersensitivity reactions requiring hospitalization), have been reported with PRALUENT treatment. If signs or symptoms of serious allergic reactions occur, discontinue treatment with PRALUENT, treat according to the standard of care, and monitor until signs and symptoms resolve
  • The most commonly occurring adverse reactions in clinical trials in primary hyperlipidemia (including heterozygous familial hypercholesterolemia (HeFH)) (≥5% of patients treated with PRALUENT and occurring more frequently than with placebo) are nasopharyngitis, injection site reactions, and influenza
  • The most commonly occurring adverse reactions in the cardiovascular outcomes trial (>5% of patients treated with PRALUENT and occurring more frequently than placebo) were non-cardiac chest pain, nasopharyngitis, and myalgia
  • In the primary hyperlipidemia (including HeFH) clinical trials, local injection site reactions including erythema/redness, itching, swelling, and pain/tenderness were reported more frequently in patients treated with PRALUENT 75 mg and/or 150 mg every 2 weeks (7.2% versus 5.1% for PRALUENT and placebo, respectively). Few patients discontinued treatment because of these reactions (0.2% versus 0.4% for PRALUENT and placebo, respectively), but patients receiving PRALUENT had a greater number of injection site reactions, had more reports of associated symptoms, and had reactions of longer average duration than patients receiving placebo
  • The once-monthly (Q4W) 300mg dosing regimen had a higher rate of local injection site reactions as compared to PRALUENT 75mg Q2W or placebo (16.6%, 9.6%, and 7.9%, respectively) in a trial in which all patients received an injection of drug or placebo every 2 weeks to maintain the blind. The discontinuation rate due to injection site reactions was 0.7% in the 300 mg Q4W arm and 0% in the other 2 arms
  • In a cardiovascular outcomes trial, local injection site reactions were reported in 3.8% of patients treated with PRALUENT versus 2.1% patients treated with placebo, and led to permanent discontinuation in 0.3% of patients versus <0.1% of patients, respectively
  • In the primary hyperlipidemia trials, liver-related disorders (primarily related to abnormalities in liver enzymes) were reported in 2.5% of patients treated with PRALUENT and 1.8% of patients treated with placebo, leading to treatment discontinuation in 0.4% and 0.2% of patients, respectively. Increases in serum transaminases to greater than 3 times the upper limit of normal occurred in 1.7% of patients treated with PRALUENT and 1.4% of patients treated with placebo
  • In the primary hyperlipidemia trials, the most common adverse reactions leading to treatment discontinuation in patients treated with PRALUENT were allergic reactions (0.6% versus 0.2% for PRALUENT and placebo, respectively) and elevated liver enzymes (0.3% versus <0.1%)
  • PRALUENT is a human monoclonal antibody. As with all therapeutic proteins, there is a potential for immunogenicity with PRALUENT

*

Back to the top ▲
ASCVD = atherosclerotic cardiovascular disease; HeFH = heterozygous familial hypercholesterolemia.
References:
  1. Grundy SM, Stone NJ, Bailey AL, et al.
    AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/
    AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. J Am Coll Cardiol. 2018; https://doi.ord/10.1016/j.jacc.2018.11.003.
  2. Schwartz GG, Steg PG, Szarek M, et al; for the ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379:2097-2107.
  3. PRALUENT® (alirocumab) Prescribing Information. Sanofi and Regeneron Pharmaceuticals.
  4. Bhatt DL, Eagle KA, Ohman EM, et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA. 2010;304:1350-1357.

© 2019 Sanofi US and Regeneron Pharmaceuticals, Inc.  All rights reserved.

Legal Disclaimer Information | Privacy Policy

Questions or Comments? Click here to contact Sanofi US or call 1-877-734-6777 to contact Regeneron Pharmaceuticals, Inc.
This site is intended for U.S. Healthcare Professionals Only.

SAUS.PRL.19.02.1357c Last Update: May 2019

Sanofi US is hosting this website on behalf of Sanofi and Regeneron Pharmaceuticals, Inc.

IMPORTANT SAFETY INFORMATION
  • PRALUENT is contraindicated in patients with a history of a serious hypersensitivity reaction to PRALUENT, including hypersensitivity vasculitis and hypersensitivity reactions requiring hospitalization
  • Hypersensitivity reactions (e.g., pruritus, rash, urticaria), including some serious events (e.g., hypersensitivity vasculitis and hypersensitivity reactions requiring hospitalization), have been reported with PRALUENT treatment. If signs or symptoms of serious allergic reactions occur, discontinue treatment with PRALUENT, treat according to the standard of care, and monitor until signs and symptoms resolve